ARC-DS

Researchers from Kings College London, part of the LonDownS team, are conducting a study about how parts of the brain work in people who have Down syndrome.

Please note that the DSA supports the aims of this study but any text describing/advertising the study is provided by the research team.


 

The purpose of this research study is to identify biological and behavioral markers, such as blood and questionnaire data, that help us understand risk and protective factors in individuals who have Down syndrome (DS) compared to those who don’t have Down syndrome.

The ultimate goal is to develop a digital cognitive assessment that is sensitive to Alzheimer’s disease (AD) biomarkers and clinical progression in individuals with DS-associated AD.

  • Participants: individuals with Down syndrome who are 30-60 years old.
  • Study partner questionnaires: on the phone or in-person.
  • Cognitive assessments.
  • Clinical exams.
  • Blood samples.
  • Remote cognitive assessments: done via smartphone (every 6 months).
  • Follow up Assessments (annually).

 

Want to find out more?

Download the following information sheets/flyers.

You can visit the LonDownS research team’s Facebook and X (formerly Twitter) profiles.

If you would like to take part, please email downsyndrome@kcl.ac.uk or call 020 7848 3626.

 

About the Research Team

Prof. Andre Strydom

Andre is a Professor in Intellectual Disabilities and a specialist in the Psychiatry of Intellectual disabilities. Professor Strydom is an expert in ageing-related issues and the cognitive issues associated with Down syndrome (trisomy 21), including Alzheimer’s disease. He leads the LonDownS Team.

Anna Williams

Anna is a research assistant for the LonDownS project, which focuses on biomarkers and risk factors for the early development of Alzheimer’s Disease in people with Down Syndrome. Her research interests focus on Alzheimer’s Disease, cognition and Down Syndrome.

Mona Beidas

Mona is a PhD student and member of the LonDownS team at King’s College London. Her research focuses on how neuroimaging can improve the detection and understanding of cerebral amyloid angiopathy, particularly in people with Down syndrome, with the aim of supporting earlier diagnosis and improved clinical outcomes.